Pomyelo 4mg capsules | Pomalidomide | MHP

POMYELO 4MG

MULTIPLE MYELOMA

DESCRIPTION

Pomalidomide is sold under the brand name Pomyelo 4mg and it belongs to anti-neoplastic drugs

Pomyelo 4mg is doable as orally bioavailable thalidomide derivative associated with numerous therapeutic activities such as: immune modulatory, anti-angiogenesis, anti-neoplastic.

Pomyelo 4mg combination with dexamethasone will cause liver injury

CLINICAL USE

The primary indication of Pomyelo 4mg capsules is used in the treatment of Multiple Myeloma condition.

In this condition, Pomyelo 4mg capsules is used by combining with dexamethasone.

Pomyelo 4mg capsules are applicable in;

Previously the Patients treated with two treatment such as proteasome inhibitor & Lenalidomide.

Patients who are suffered with disease progression condition

Pomyelo 4mg treatment should be followed within 60 days in patients who are concluded the last treatment.

MECHANISM OF ACTION

Pomyelo has three primary pharmacological activities against cancer cells.
Pomalidomide includes in the way cancer proliferation and provoke the apoptosis of cancer cells.
Pomalidomide enhance the T cell & natural killer cells interceding immunity & inhibits the formation of pro inflammatory cytokines from monocytes.
Pomalidomide forbid the new cell formation. The binding of Pomalidomide to active site of targeted cell causes inhibition of ubiquitin ligase action.

Brand : Pomyelo
Ingredients : Pomalidomide
Strength : 4mg
Manufactured : Intas Pharma
Package : 21 capsules

For More Information


PHARMACOKINETICS


The time to high serum concentration of Pomalidomide is reaches between 2 to 3 hours.
It should be administered with or without food. Hence No effect of food should be produced;
Volume of distribution of Pomalidomide is between 62 & 138L in steady state.
The Pomalidomide distribution by 67% of serum level at after 4 hours of drug intake.
human plasma protein by bounding range of 12% & 44%.
Hepatically mediated through CYP1A2, CYP3A4 is Pomalidomide is metabolized.
Pomalidomide clearance value is 7 to 10L/hr.
Doses are excreted via urine 73% & feces 15% respectively.
Doses are excreted as an unchanged form via urine 2% & feces 8%.
Pomalidomide half-life period is 9.5 hours.


DOSAGE MANAGEMENT

PRECAUTIONS

WARNING

During multiple myeloma malignancies;
The dosage recommendation of Pomyelo 4mg is 4mg should be administered as a single dose for 1 to 21 days of successive 28-day cycles.
Pomyelo is combined with dexamethasone with low dose.
Administrate Dexamethasone on day 1, 8, 15 & 22 of each 28-day cycle.
The prescribed dose of dexamethasone is 40mg should be administered the patient having weight about ≤ 75kg.
The prescribed dose of dexamethasone is 20mg given for patient’s weight Greater than 75kg
Dosage alteration during hematological toxicities;
Neutropenia;
ANC <500/mcL: Pomyelo treatment should be postponed and check the CBC weekly.
ANC ≥ 500/mcL: Pomyelo therapy should be continued by 3mg/day
For each successive drop <500/mcL: Pomyelo 4mg should be postponed.
ANC ≥ 500/mcL: Continue the Pomyelo therapy with 1mg/day.
Thrombocytopenia;
Platelets count <25000/mcL: Pomyelo therapy should be postponed and check CBC
Platelets count ≥50000/mcL: 3mg of Pomyelo should be taken daily
With strong CYP1A2;
Pomyelo combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.
In renal damaged patients;
In severe renal impaired patients, the suggested dose of Pomyelo is 3mg per day.
In hepatic impaired patients;
The advised dose is 3mg/day & in severe condition, the suggested dose is 2mg/day given for mild to moderate patients.

FOR MORE INFO

CONTACT NO : +91-9940472902

EMAIL : millionhealthpharmaceuticals@gmail.com

WEBSITE URL : https://millionpharma.com/pomyelo-4mg.php